The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1367
ISSUE1367
June 27, 2011
Ipilimumab (Yervoy) for Metastatic Melanoma
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ipilimumab (Yervoy) for Metastatic Melanoma
June 27, 2011 (Issue: 1367)
The FDA has approved ipilimumab (Yervoy – Bristol-Myers Squibb), a recombinant human monoclonal antibody, for treatment of unresectable or metastatic melanoma.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.